Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome

Wenxiu He,Jiahe Wei,Xing Liu,Zhongyin Zhang,Rongjie Huang,Zhiyuan Jiang

DOI: https://doi.org/10.1038/s41598-024-62465-6

IF: 4.6

2024-05-25

Scientific Reports

Abstract:Pathological cardiac hypertrophy is an important cause of heart failure(HF). Recent studies reveal that glucagon-like peptide-1 receptor (GLP1R) agonists can improve mortality and left ventricular ejection fraction in the patients with type 2 diabetes and HF. The present study aims to investigate whether semaglutide, a long-acting GLP1R agonist, can ameliorate cardiac hypertrophy induced by pressure overload, and explore the potential mechanism. The rats were performed transverse aortic constriction (TAC) to mimic pressure overload model. The rats were divided into four groups including Sham, TAC, TAC + semaglutide, and TAC + semaglutide + HCQ (hydroxychloroquine, an inhibitor of mitophagy). The rats in each experimental group received their respective interventions for 4 weeks. The parameters of left ventricular hypertrophy(LVH) were measured by echocardiography, Hematoxylin–eosin (HE) staining, western-blot and immunohistochemistry (IHC), respectively. The changes of mitophagy were reflected by detecting cytochrome c oxidase subunit II (COXII), LC3II/LC3I, mitochondria, and autophagosomes. Meanwhile, NLRP3, Caspase-1, and interleukin-18 were detected to evaluate the activation of NLRP3 inflammasome in each group. The results suggest that LVH, impaired mitophagy, and activation of NLRP3 inflammasome were present in TAC rats. Semaglutide significantly reduced LVH, improve mitophagy, and down-regulated NLRP3 inflammatory signal pathway in TAC rats. However, the reversed effect of semaglutide on cardiac hypertrophy was abolished by HCQ, which restored the activation of NLRP3 inflammasome suppressed by improved mitophagy. In conclusion, semaglutide ameliorates the cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome. Semaglutide may be a novel potential option for intervention of cardiac hypertrophy induced by pressure overload.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem this paper attempts to address is whether the long-acting glucagon-like peptide-1 receptor (GLP1R) agonist semaglutide can improve cardiac hypertrophy induced by pressure overload and to explore its potential mechanisms.

Specifically, the paper establishes a rat model of transverse aortic constriction (TAC) to simulate pressure overload-induced left ventricular hypertrophy (LVH) and then observes the effect of semaglutide on this hypertrophy. The study found that semaglutide significantly alleviated ventricular hypertrophy in TAC rats and inhibited the activation of the NLRP3 inflammasome by improving cardiac autophagy function. Furthermore, when the autophagy inhibitor hydroxychloroquine (HCQ) was used, the ameliorative effect of semaglutide on cardiac hypertrophy was reversed, further confirming that the mechanism of semaglutide's action is related to the improvement of autophagy function.

Therefore, this study aims to demonstrate that semaglutide alleviates pressure overload-induced cardiac hypertrophy by inhibiting the activation of the NLRP3 inflammasome through the improvement of cardiac autophagy function. This finding may provide a new potential strategy for the treatment of hypertension-related cardiac hypertrophy.